医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s Q2 & H1 FY19 Financial Results

2018年10月26日 PM10:22
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter and half year ended September 30, 2018 under International Financial Reporting Standards (IFRS).

Q2 Performance Summary       H1 Performance Summary
 

Rs. 3,798 Cr

Rs. 7,519 Cr

Revenue

Revenue

[Up: 2% QoQ; 7% YoY]

[Up: 10% YoY]

 

55.00%

55.40%

Gross Margin

Gross Margin

[Q1 FY19: 55.7%; Q2 FY18: 53.3%]

[H1 FY17: 52.5%]

 

Rs. 1,237 Cr

Rs. 2,448 Cr

SGNA expenses

SGNA expenses

[Up: 2% QoQ, 12% YoY]

[Up: 7% YoY]

 

Rs. 412 Cr

Rs. 828 Cr

R&D expenses

R&D expenses

[10.8% of Revenues]

[11.0% of Revenues]

 

Rs. 578 Cr

Rs. 1,079 Cr

Profit before Tax

Profit before Tax

[Up: 15% QoQ; 49% YoY]

[Up: 132%]

 

Rs. 504 Cr

Rs.960 Cr

Profit after Tax

Profit after Tax

[Up: 10% QoQ, 77% YoY]

[Up: 179%]

 

Commenting on the results, Co-chairman and CEO, G.V. Prasad said, “I am encouraged with our performance and progress in the second quarter. Our continuous focus on execution, operational efficiency and cost optimization are showing results. Looking ahead, our priority will be to resolve pending regulatory issues, and continue to work on execution and cost structures that will enable affordable medicines for more patients.”

   

All amounts in millions, except EPS

All US dollar amounts based on convenience translation rate of I USD = Rs. 72.54

     
Dr. Reddy’s Laboratories Limited and Subsidiaries
 

Consolidated Income Statement

 
                     
Particulars Q2 FY19 Q2 FY18 YoY
Gr %
Q1 FY19 QoQ
Gr%
  ($)   (Rs.)   ($)   (Rs.)     ($)   (Rs.)  
Revenues 524   37,978 489   35,460 7 513   37,207 2
Cost of Revenues   235   17,081   228   16,559   3   227   16,479   4
Gross Profit   288   20,897   261   18,901   11   286   20,728   1
Operating Expenses
Selling, General & Administrative expenses 171 12,372 152 11,032 12 167 12,106 2
Research and Development expenses 57 4,120 58 4,175 (1) 57 4,157 (1)
Other (income) / expense, net   (9)   (641)   (2)   (114)   463   (4)   (303)   112
Results from operating activities   70   5,046   52   3,808   33   66   4,768   6
Net finance (income) / expense (9) (625) 0.3 24 (2) (156) 301
Share of (profit) / loss of equity accounted investees, net of tax   (1)   (109)   (1)   (92)   17   (1)   (83)   30
Profit before income tax   80   5,780   53   3,876   49   69   5,007   15
Income tax expense   10   742   14   1,027   (28)   6   446   67
Profit for the period   69   5,038   39   2,849   77   63   4,561   10
                                 
Diluted Earnings Per Share (EPS)   0.42   30.31   0.24   17.15   77   0.38   27.45   10
 
                     
As % to Revenues

Q2
FY19

Q2
FY18

Q1
FY19

Gross Profit 55.0 53.3 55.7
SG&A 32.6 31.1 32.5
R&D 10.8 11.8 11.2
EBITDA 22.8 19.4 21.7
PBT 15.2 10.9 13.5
PAT 13.3 8.0 12.3
 

EBITDA Computation

                 
Particulars   Q2 FY19 Q2 FY18 Q1 FY19
  ($)   (Rs.) ($)   (Rs.) ($)   (Rs.)
Profit before Income Tax 80   5,780 53   3,876 69   5,007
Interest (income) net* (2) (132) 1 72 (1) (46)
Depreciation# 28 2,033 29 2,078 31 2,214
Amortization#   13   965 12   862 12   896
EBITDA   119   8,646 95   6,888 111   8,071

* Includes income from Investments

# includes impairment charge

 

All amounts in millions, except EPS

 

All US dollar amounts based on convenience translation rate of I USD = Rs.72.54

   

Key Balance Sheet Items

             
Particulars As on 30th Sep, 2018   As on 30th June 2018   As on 30th Sep 2017
  ($)   (Rs.)   ($)   (Rs.)   ($)   (Rs.)
Cash and cash equivalents and other investments   287   20,837   235   17,047   232   16,793
Trade receivables (current & non-current)   639   46,317   663   48,095   582   42,203
Inventories   448   32,490   434   31,498   372   26,998
Property, plant and equipment   781   56,640   786   57,020   798   57,905
Goodwill and Other Intangible assets   707   51,290   679   49,289   684   49,634
Loans and borrowings (current & non-current)   765   55,522   748   54,273   740   53,668
Trade and other payables   194   14,073   204   14,816   196   14,193
Equity   1,812   1,31,446   1,798   1,30,430   1,680   1,21,840
     

<td class="bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebotto

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • GI Dynamics Announces Close of Second Tranche of Placement and Grant of Options to CEO
  • 瑞思迈完成对MatrixCare的收购
  • レスメドがマトリックスケアの買収を完了
  • SpinalCyte宣布,注射CybroCell™后,MRI转归可维持12个月
  • コックスバザールの病院で14万人のロヒンギャ難民に24時間体制の医療援助を提供
  • Revenue Mix by Segment

                         
    Particulars   Q2 FY19   Q2 FY18   YoY
    Growth %
      Q1 FY19   QoQ
    Growth %
      (Rs.)   (Rs.)     (Rs.)  
    Global Generics